Geraldine Henwood - Dec 15, 2021 Form 4 Insider Report for Baudax Bio, Inc. (BXRX)

Role
President and CEO, Director
Signature
By: /s/ Richard Casten, Attorney-in-fact
Stock symbol
BXRX
Transactions as of
Dec 15, 2021
Transactions value $
-$5,777
Form type
4
Date filed
12/23/2021, 04:45 PM
Previous filing
Dec 14, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BXRX Common Stock Tax liability -$5.78K -18.6K -5.24% $0.31 337K Dec 15, 2021 Direct F1
holding BXRX Common Stock 20K Dec 15, 2021 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BXRX Stock Option (right to buy) Award $0 +821K $0.00 821K Dec 22, 2021 Common Stock 821K $1.70 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
F2 The Option was granted on January 20, 2021, contingent upon the Company's board of directors approval of the increase in the number of shares available for issuance under the Company's 2019 Equity Incentive Plan pursuant to the evergreen provision therein.
F3 The stock option vests in equal monthly installments over 48 months, beginning on February 20, 2021, subject to continued service to the Company.